AchieveRx Q3 10-Q: $97.0M Nine-Month Loss, $201.5M Cash, NDA Resubmission Set for Q4
ACHV has more than doubled off its 52-week low of $2.62.
Summary
AchieveRx's Q3 10-Q shows a $97.0M nine-month net loss that is mostly a non-cash $41.6M warrant remeasurement, $201.5M of cash and securities, and an NDA resubmission still targeted for Q4 2026.
Key Events · Earnings and Guidance · ACHV
-
Nine-Month Loss Driven by Non-Cash Warrant Charge
Net loss was $97.0M for the nine months ended September 30, 2026 versus $40.0M a year ago, including a $41.6M non-cash change in fair value of warrant liability and $8.8M of warrant issuance costs. Q3 alone was a $12.1M loss versus $14.4M a year ago.
-
Cash Position and Burn
Cash, cash equivalents and marketable securities totaled $201.5M at September 30, 2026, up from $36.4M at December 31, 2025, against $26.1M of net cash used in operations for the nine months.
-
Warrants Moved to Equity, Ending Remeasurement
Stockholders approved raising authorized shares from 150,000,000 to 300,000,000 on July 2, 2026; $175.8M of warrant fair value and $0.6M of pre-funded warrant fair value were reclassified to additional paid-in capital and are no longer remeasured.
-
Sopharma Arbitration Pending, No Liability Booked
Sopharma filed an arbitration demand on July 17, 2026 alleging breach of the supply agreement and seeking an order requiring it be named designated manufacturer in any future NDA. Achieve disputes the claims and has recorded no liability because a loss range is not estimable.
Analysis · ACHV · Life Sciences
The headline loss is mostly accounting noise. Of the $97.0M nine-month net loss, $41.6M is a non-cash mark-to-market loss on warrants that were reclassified to equity on July 2, 2026, and $8.8M is warrant issuance costs expensed for the same reason. Neither is a cash outflow, and the warrants are no longer remeasured now that they sit in equity. What matters is the balance sheet: $201.5M of cash and securities against $26.1M of nine-month operating cash burn leaves a long runway into the cytisinicline launch. The open risk is the Sopharma arbitration filed July 17, 2026, which seeks an order forcing Sopharma into any future NDA as designated manufacturer; no liability is booked because the company says a loss range is not estimable. The NDA resubmission naming Adare as finished-product manufacturer is still guided to Q4 2026, with potential approval by end-Q2 2027.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACHV was trading at $6.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $697.7M. The 52-week trading range was $2.62 to $8.64. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.